These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 17140572

  • 21. A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization.
    Barmat LI, Chantilis SJ, Hurst BS, Dickey RP.
    Fertil Steril; 2005 Feb; 83(2):321-30. PubMed ID: 15705369
    [Abstract] [Full Text] [Related]

  • 22. Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon).
    de Jong D, Macklon NS, Eijkemans MJ, Mannaerts BM, Coelingh Bennink HJ, Fauser BC, Ganirelix Dose-Finding Study Group.
    Fertil Steril; 2001 Apr; 75(4):688-93. PubMed ID: 11287020
    [Abstract] [Full Text] [Related]

  • 23. Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression.
    Cavagna M, Maldonado LG, de Souza Bonetti TC, de Almeida Ferreira Braga DP, Iaconelli A, Borges E.
    Fertil Steril; 2010 Jun; 94(1):167-72. PubMed ID: 19342035
    [Abstract] [Full Text] [Related]

  • 24. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
    Humaidan P, Bredkjaer HE, Bungum L, Bungum M, Grøndahl ML, Westergaard L, Andersen CY.
    Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
    [Abstract] [Full Text] [Related]

  • 25. Effect of luteal-phase support on endometrial L-selectin ligand expression after recombinant follicle-stimulating hormone and ganirelix acetate for in vitro fertilization.
    Vlahos NF, Lipari CW, Bankowski B, Lai TH, King JA, Shih IeM, Fragakis K, Zhao Y.
    J Clin Endocrinol Metab; 2006 Oct; 91(10):4043-9. PubMed ID: 16868054
    [Abstract] [Full Text] [Related]

  • 26. Progesterone levels in letrozole associated controlled ovarian stimulation for fertility preservation in breast cancer patients.
    Goldrat O, Gervy C, Englert Y, Delbaere A, Demeestere I.
    Hum Reprod; 2015 Sep; 30(9):2184-9. PubMed ID: 26109617
    [Abstract] [Full Text] [Related]

  • 27. Suppression of luteal function by a luteinizing hormone-releasing hormone antagonist during the early luteal phase in the stumptailed macaque monkey and the effects of subsequent administration of human chorionic gonadotropin.
    Fraser HM, Nestor JJ, Vickery BH.
    Endocrinology; 1987 Aug; 121(2):612-8. PubMed ID: 3109885
    [Abstract] [Full Text] [Related]

  • 28. Luteal supplementation in in vitro fertilization: more questions than answers.
    Hubayter ZR, Muasher SJ.
    Fertil Steril; 2008 Apr; 89(4):749-58. PubMed ID: 18406833
    [Abstract] [Full Text] [Related]

  • 29. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists.
    Kolibianakis EM, Schultze-Mosgau A, Schroer A, van Steirteghem A, Devroey P, Diedrich K, Griesinger G.
    Hum Reprod; 2005 Oct; 20(10):2887-92. PubMed ID: 15979994
    [Abstract] [Full Text] [Related]

  • 30. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H, Huang GN, Cao YX, Zhong Y, Huang YH, Zhu GJ, Zhou LM, Chen ZJ, Shi JZ, Zeng Y, Weng N, Huang XF, Yang J, Zhu YM, Li YP, Yi D, Zhuang GL.
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [Abstract] [Full Text] [Related]

  • 31. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C.
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [Abstract] [Full Text] [Related]

  • 32. Prospective randomized comparison of human chorionic gonadotropin versus intramuscular progesterone for luteal-phase support in assisted reproduction.
    Araujo E, Bernardini L, Frederick JL, Asch RH, Balmaceda JP.
    J Assist Reprod Genet; 1994 Feb; 11(2):74-8. PubMed ID: 7819706
    [Abstract] [Full Text] [Related]

  • 33. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
    Hohmann FP, Macklon NS, Fauser BC.
    J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
    [Abstract] [Full Text] [Related]

  • 34. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization.
    Fauser BC, de Jong D, Olivennes F, Wramsby H, Tay C, Itskovitz-Eldor J, van Hooren HG.
    J Clin Endocrinol Metab; 2002 Feb; 87(2):709-15. PubMed ID: 11836309
    [Abstract] [Full Text] [Related]

  • 35. The early luteal hormonal profile in IVF patients triggered with hCG.
    Vuong LN, Ho TM, Pham TD, Ho VNA, Andersen CY, Humaidan P.
    Hum Reprod; 2020 Jan 01; 35(1):157-166. PubMed ID: 31967304
    [Abstract] [Full Text] [Related]

  • 36. Luteal estrogen supplementation in pregnancies associated with low serum estradiol concentrations.
    Kaider AS, Coulam CB.
    Early Pregnancy (Cherry Hill); 2000 Jul 01; 4(3):191-9. PubMed ID: 11727011
    [Abstract] [Full Text] [Related]

  • 37. Initiation of ovarian stimulation independent of the menstrual cycle: a case-control study.
    Buendgen NK, Schultze-Mosgau A, Cordes T, Diedrich K, Griesinger G.
    Arch Gynecol Obstet; 2013 Oct 01; 288(4):901-4. PubMed ID: 23545834
    [Abstract] [Full Text] [Related]

  • 38. The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetrorelix.
    Albano C, Grimbizis G, Smitz J, Riethmüller-Winzen H, Reissmann T, Van Steirteghem A, Devroey P.
    Fertil Steril; 1998 Aug 01; 70(2):357-9. PubMed ID: 9696235
    [Abstract] [Full Text] [Related]

  • 39. Hormonal profiles in successful and unsuccessful implantation in IVF-ET after combined GnRH agonist/gonadotropin treatment for superovulation and hCG luteal support.
    Balasch J, Creus M, Fábregues F, Carmona F, Casamitjana R, Peñarrubia J, Rivera F, Vanrell JA.
    Gynecol Endocrinol; 1995 Mar 01; 9(1):51-8. PubMed ID: 7793300
    [Abstract] [Full Text] [Related]

  • 40. A randomized controlled dose-response pilot study of addition of hCG to recombinant FSH during controlled ovarian stimulation for in vitro fertilization.
    Thuesen LL, Loft A, Egeberg AN, Smitz J, Petersen JH, Andersen AN.
    Hum Reprod; 2012 Oct 01; 27(10):3074-84. PubMed ID: 22791754
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.